# Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients

> **NCT03825887** · PHASE3 · COMPLETED · sponsor: **Children's Cancer Hospital Egypt 57357** · enrollment: 80 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Stem Cell Leukemia

## Interventions

- **DRUG:** Nalbuphine
- **DRUG:** Morphine

## Key facts

- **NCT ID:** NCT03825887
- **Lead sponsor:** Children's Cancer Hospital Egypt 57357
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03825887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03825887, "Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03825887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*